🔗 Share this article World Health Organization Issues Warning Over Severe Scarcity of Weight-Loss Medications Under one in 10 people who could benefit from GLP-1 drugs including Wegovy have access to them, warns the World Health Organization as it publishes its first advice on the drugs. With over a billion individuals worldwide now obese, it is calling for more widespread and fairer access to this class of drugs. Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention. "Our latest guidelines affirms that obesity is a long-term condition that can be treated with comprehensive and continuous care," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are major obstacles to universal availability to the injections that can aid individuals in losing substantial weight, says the organization. Weight-Loss Drug Scarcity Despite the current most favorable case, the manufacturing of these medications would only suffice for about 100 million people – less than 10% of eligible patients, as stated by the WHO. The advice urges governments and firms to increase availability, by measures including patent sharing. A patent on the active ingredient – the primary ingredient of the drug Wegovy – is due to expire in multiple countries in 2026. The Way Obesity Injections Function GLP-1 drugs imitate a body's own hormone to reduce digestion speed, reduce hunger and boost feelings of fullness so users consume fewer calories. Individuals usually see weight reduction in the initial weeks of commencing the regular doses. Evidence points to users may regain a significant portion a year later of stopping the treatment, as their typical food cravings return. To be overweight or obese raises your risk for contracting medical conditions, such as type 2 diabetes, heart disease, stroke, and specific cancers. Obesity affects people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
Under one in 10 people who could benefit from GLP-1 drugs including Wegovy have access to them, warns the World Health Organization as it publishes its first advice on the drugs. With over a billion individuals worldwide now obese, it is calling for more widespread and fairer access to this class of drugs. Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention. "Our latest guidelines affirms that obesity is a long-term condition that can be treated with comprehensive and continuous care," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are major obstacles to universal availability to the injections that can aid individuals in losing substantial weight, says the organization. Weight-Loss Drug Scarcity Despite the current most favorable case, the manufacturing of these medications would only suffice for about 100 million people – less than 10% of eligible patients, as stated by the WHO. The advice urges governments and firms to increase availability, by measures including patent sharing. A patent on the active ingredient – the primary ingredient of the drug Wegovy – is due to expire in multiple countries in 2026. The Way Obesity Injections Function GLP-1 drugs imitate a body's own hormone to reduce digestion speed, reduce hunger and boost feelings of fullness so users consume fewer calories. Individuals usually see weight reduction in the initial weeks of commencing the regular doses. Evidence points to users may regain a significant portion a year later of stopping the treatment, as their typical food cravings return. To be overweight or obese raises your risk for contracting medical conditions, such as type 2 diabetes, heart disease, stroke, and specific cancers. Obesity affects people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.